Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CORY J RUBIN

Allopathic & Osteopathic Physicians Dermatology Clinical & Laboratory Dermatological Immunology

NPI
1780888974
CMS profile
983813
Location
WATERFORD, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$605,793.52

734 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 15 of 15; records 701–734 of 734 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CORY J RUBIN

NPI 1780888974 · CMS profile ID 983813

Allopathic & Osteopathic Physicians / Dermatology / Clinical & Laboratory Dermatological Immunology

WATERFORD, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 15 of 15; records 701–734 of 734 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780888974?year=2019&recipient=provider&page=15#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CORY J RUBIN, NPI 1780888974, CMS profile ID 983813. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 15 of 15; records 701–734 of 734 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780888974?year=2019&recipient=provider&page=15#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CORY J RUBIN, NPI 1780888974, CMS profile ID 983813. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 15 of 15; records 701–734 of 734 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780888974?year=2019&recipient=provider&page=15#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CORY J RUBIN, NPI 1780888974, CMS profile ID 983813, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 15 of 15; records 701–734 of 734 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1780888974?year=2019&recipient=provider&page=15#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

734 matching records · $605,793.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 734 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 701–734 of 734.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $452.6001/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659807979 CMS
Celgene Corporation $4,305.0001/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672824017 CMS
Celgene Corporation $1,000.0001/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672824721 CMS
Celgene Corporation $78.9301/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672830471 CMS
Celgene Corporation $16.5901/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672730066 CMS
Celgene Corporation $5,535.0001/12/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672831079 CMS
Celgene Corporation $224.8801/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672836213 CMS
Celgene Corporation $56.3701/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672836219 CMS
Celgene Corporation $316.3901/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672843847 CMS
Celgene Corporation $53.6801/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672848394 CMS
Celgene Corporation $56.6601/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672850131 CMS
Celgene Corporation $38.9201/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672863341 CMS
Celgene Corporation $119.6701/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673014217 CMS
Celgene Corporation $4.4501/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672730061 CMS
PFIZER INC. $2.7301/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672703369 CMS
PFIZER INC. $3.3601/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672703373 CMS
Novartis Pharmaceuticals Corporation $1,248.0501/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808043 CMS
Novartis Pharmaceuticals Corporation $3,600.0001/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808045 CMS
Novartis Pharmaceuticals Corporation $17.1701/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808047 CMS
Novartis Pharmaceuticals Corporation $10.8001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808049 CMS
Novartis Pharmaceuticals Corporation $3,000.0001/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808065 CMS
Novartis Pharmaceuticals Corporation $119.9301/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808067 CMS
PFIZER INC. $5.0001/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672701913 CMS
PFIZER INC. $4.8401/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672725755 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.9001/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684600683 CMS
PFIZER INC. $2,000.0001/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672701937 CMS
UCB, Inc. $2,500.0001/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688234083 CMS
Novartis Pharmaceuticals Corporation $417.5201/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808069 CMS
Novartis Pharmaceuticals Corporation $386.6301/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808071 CMS
Novartis Pharmaceuticals Corporation $6,200.0001/05/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808073 CMS
Novartis Pharmaceuticals Corporation $57.4901/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808075 CMS
Novartis Pharmaceuticals Corporation $121.7201/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808077 CMS
Novartis Pharmaceuticals Corporation $411.0001/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659808149 CMS
Smith+Nephew, Inc. $9.0001/04/2019 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 699450559 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $605,793.52 734
PY2020 $289,061.89 331
PY2021 $269,579.68 335
PY2022 $543,351.03 605
PY2023 $783,235.52 802
PY2024 $812,494.11 749
PY2025 $554,753.48 573

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $35,174.70 12
PY2025 Principal investigator $204,463.37 114
PY2024 Recipient $32,159.90 4
PY2024 Principal investigator $133,232.00 158
PY2023 Recipient $250.00 1
PY2023 Principal investigator $124,762.00 88
PY2022 Recipient $3,537.03 6
PY2022 Principal investigator $30,481.00 27
PY2021 Principal investigator $8,799.00 14
PY2020 Recipient $10,252.00 13
PY2019 Principal investigator $2,540.00 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

126 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient SANOFI US SERVICES INC. $1,271.70 12/19/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226123198
Principal investigator 1 Incyte Corporation $803.50 12/08/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557802
Principal investigator 1 ABBVIE INC. $2,314.27 12/04/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527872
Principal investigator 1 Incyte Corporation $1,520.10 12/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240557742
Recipient SANOFI US SERVICES INC. $3,158.10 12/04/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226123194
Principal investigator 1 Incyte Corporation $5,095.00 12/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240557748
Principal investigator 1 Incyte Corporation $1,560.00 12/01/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557754
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557759
Principal investigator 1 Incyte Corporation $2.04 12/01/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557771
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557784
Principal investigator 1 Incyte Corporation $6,000.00 12/01/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557788
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557795
Principal investigator 1 Incyte Corporation $18.96 12/01/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557807
Principal investigator 1 Incyte Corporation $1,879.20 11/24/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557766
Principal investigator 1 PFIZER INC. $442.00 11/19/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228720251
Principal investigator 1 PFIZER INC. $442.00 11/19/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228739406
Principal investigator 1 PFIZER INC. $442.00 11/19/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228739434
Principal investigator 1 PFIZER INC. $1,369.00 11/19/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228739549
Principal investigator 1 PFIZER INC. $442.00 11/19/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228747387
Principal investigator 1 PFIZER INC. $442.00 11/19/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228747734
Principal investigator 1 Incyte Corporation $1,458.90 11/06/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240557736
Principal investigator 1 ABBVIE INC. $7,066.21 11/04/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520473
Recipient LEO Pharma AS $990.00 11/03/2025 Covered Recipient Physician TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB No dispute reported 06/30/2026 1251992180
Recipient LEO Pharma AS $781.00 11/03/2025 Covered Recipient Physician TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBED TRALOKINUMAB No dispute reported 06/30/2026 1251992183
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Michigan Dermatology Institute
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235995711
Principal investigator 1 PFIZER INC. $13,000.00 10/29/2025 Non-covered Recipient Entity
Michigan Dermatology Institute
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228720765
Principal investigator 1 ABBVIE INC. $7,605.19 10/09/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202514959
Recipient SANOFI US SERVICES INC. $2,048.40 10/08/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226123190
Principal investigator 1 Incyte Corporation $11,688.30 10/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240557729
Principal investigator 1 Incyte Corporation $1,203.30 10/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557778
Principal investigator 1 Incyte Corporation $45.00 10/01/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240557818
Recipient SANOFI US SERVICES INC. $3,951.00 09/17/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226123186
Principal investigator 1 Incyte Corporation $2,965.50 09/12/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240557657
Principal investigator 1 ABBVIE INC. $14,262.40 09/03/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202508226
Principal investigator 1 Incyte Corporation $28,222.20 08/21/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) No dispute reported 06/30/2026 1240557652
Recipient SANOFI US SERVICES INC. $4,096.80 08/20/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226123181
Principal investigator 1 ABBVIE INC. $3,583.77 08/05/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202502090
Principal investigator 1 Incyte Corporation $7.42 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557669
Principal investigator 1 Incyte Corporation $91.60 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557675
Principal investigator 1 Incyte Corporation $118.26 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557682
Principal investigator 1 Incyte Corporation $74.04 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557688
Principal investigator 1 Incyte Corporation $124.54 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557694
Principal investigator 1 Incyte Corporation $48.54 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557700
Principal investigator 1 Incyte Corporation $24.66 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557706
Principal investigator 1 Incyte Corporation $24.66 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557712
Principal investigator 1 Incyte Corporation $24.66 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557717
Principal investigator 1 Incyte Corporation $24.66 08/04/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557724
Recipient SANOFI US SERVICES INC. $2,664.00 07/23/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226123173
Principal investigator 1 Incyte Corporation $1,304.10 07/18/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557663
Principal investigator 1 PFIZER INC. $1,369.00 07/16/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714487
Principal investigator 1 PFIZER INC. $1,369.00 07/16/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714583
Principal investigator 1 PFIZER INC. $442.00 07/16/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714657
Principal investigator 1 PFIZER INC. $442.00 07/16/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714659
Principal investigator 1 PFIZER INC. $442.00 07/16/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714661
Principal investigator 1 ABBVIE INC. $11,522.65 07/02/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202496649
Recipient SANOFI US SERVICES INC. $11,918.70 06/27/2025 Covered Recipient Physician An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226123171
Principal investigator 1 Incyte Corporation $1,449.00 06/25/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557538
Principal investigator 1 Incyte Corporation $1,058.40 06/25/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557545
Principal investigator 1 ABBVIE INC. $1,802.58 06/03/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489371
Principal investigator 1 Incyte Corporation $10,021.31 06/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240557515
Recipient GENZYME CORPORATION $500.00 05/29/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226123178
Recipient GENZYME CORPORATION $250.00 05/29/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226123204
Principal investigator 1 Incyte Corporation $337.50 05/21/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557521
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,773.75 05/08/2025 Non-covered Recipient Entity
Michigan Dermatology Institute
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235995709
Principal investigator 1 Eli Lilly and Company $10,627.00 05/07/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187885502
Principal investigator 1 ABBVIE INC. $4,932.92 05/06/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481169
Principal investigator 1 Incyte Corporation $2,239.20 05/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557551
Principal investigator 1 Incyte Corporation $1,512.90 04/09/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557527
Principal investigator 1 ABBVIE INC. $439.30 04/03/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202471110
Principal investigator 1 Incyte Corporation $14.84 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557533
Principal investigator 1 Incyte Corporation $62.27 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557557
Principal investigator 1 Incyte Corporation $59.13 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557564
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557569
Principal investigator 1 Incyte Corporation $12.36 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557576
Principal investigator 1 Incyte Corporation $24.68 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557581
Principal investigator 1 Incyte Corporation $0.31 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557587
Principal investigator 1 Incyte Corporation $2.43 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557593
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557599
Principal investigator 1 Incyte Corporation $135.40 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557605
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557611
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557616
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557623
Principal investigator 1 Incyte Corporation $49.32 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557629
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557635
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557641
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557646
Principal investigator 1 PFIZER INC. $1,369.00 03/12/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714579
Principal investigator 1 PFIZER INC. $442.00 03/12/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714581
Principal investigator 1 PFIZER INC. $442.00 03/12/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714933
Principal investigator 1 ABBVIE INC. $8,676.29 03/06/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202456367
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557415
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557421
Principal investigator 1 Incyte Corporation $4.86 03/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557427
Principal investigator 1 Incyte Corporation $54.76 03/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557433
Principal investigator 1 Incyte Corporation $22.90 03/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557461
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557467
Principal investigator 1 Incyte Corporation $64.72 03/03/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557485
Principal investigator 1 PFIZER INC. $1,369.00 02/14/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714747
Principal investigator 1 PFIZER INC. $1,369.00 02/14/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714749
Principal investigator 1 PFIZER INC. $442.00 02/14/2025 Non-covered Recipient Entity
Cory J Rubin MD PC
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228714751
Recipient E.R. Squibb & Sons, L.L.C. $3,545.00 02/12/2025 Covered Recipient Physician A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1236002033
Principal investigator 1 Incyte Corporation $1,512.90 02/10/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557345
Principal investigator 1 ABBVIE INC. $10,506.84 02/05/2025 Non-covered Recipient Entity
CORY J RUBIN MD PC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444849
Principal investigator 1 Incyte Corporation $1,512.90 01/15/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557357
Principal investigator 1 Amgen Inc. $4,449.08 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
P2 Moderate-Severe pDLE No dispute reported 06/30/2026 1246644657
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557339
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557351
Principal investigator 1 Incyte Corporation $111.30 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557364
Principal investigator 1 Incyte Corporation $53.80 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557368
Principal investigator 1 Incyte Corporation $47.70 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557373
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557378
Principal investigator 1 Incyte Corporation $68.90 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557385
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557390
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557397
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557402
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557406
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557411
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557443
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557449
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557455
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557473
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557479
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557491
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557497
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557503
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
MICHIGAN DERMATOLOGY INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240557509